2021 Jan 26, 2:07pm
197 views 5 comments
Merck & Co said on Monday it is ending development of two potential COVID-19 vaccine candidates, V590 and V591Officials say the vaccines were well-tolerated but didn't generate enough of an immune response compared to other shots or natural infectionInstead, the New Jersey-based company says it will focus its research on therapeutic drugs, MK-7110 and MK-4482, to fight COVID-19MK-7110 protects patients from the damage of an overactive immune response to the virus while the other drug is given in the early stages of infection
Wait till pandemic is over, moderna n pfizer will get hit with lot of law suits for side effects. Glad merck didn't fall for this trap.
Rna virus mutates n there are lot of varients , so vaccine may not be effective. Instead mrk is concentrating drug which slows growth of covid n its promising.